# Decitabine, Doxorubicin, and Cyclophosphamide in Treating Children With Relapsed or Refractory Solid Tumors or Neuroblastoma

> **NCT00075634** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 21 (actual)

## Conditions studied

- Recurrent Neuroblastoma
- Unspecified Childhood Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** decitabine
- **DRUG:** doxorubicin hydrochloride
- **DRUG:** cyclophosphamide
- **BIOLOGICAL:** filgrastim
- **BIOLOGICAL:** pegfilgrastim
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00075634
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-12
- **Primary completion:** 2007-09
- **Final completion:** —
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2013-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00075634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00075634, "Decitabine, Doxorubicin, and Cyclophosphamide in Treating Children With Relapsed or Refractory Solid Tumors or Neuroblastoma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00075634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*